Trials / Terminated
TerminatedNCT02486510
Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Effect on HIV-1 cell reservoirs of the concomitant administration of intensive chemotherapy and the pharmacological blockade of CCR5 coreceptors: a pilot, open, randomized, and controlled clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maraviroc | Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery. Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2015-07-01
- Last updated
- 2015-12-18
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT02486510. Inclusion in this directory is not an endorsement.